XTSX
RP
Market cap761kUSD
Feb 28, Last price
0.02CAD
Name
Replicel Life Sciences Inc
Chart & Performance
P/E
—
P/S
3.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
22.07%
Rev. gr., 5y
23.91%
Revenues
354k
0.00%
Net income
-312k
L-75.80%
CFO
-1m
L+0.33%
Earnings
May 14, 2025
Profile
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 354 0.00% | 354 0.00% | |||||||
Cost of revenue | 1,741 | 1,749 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,388) | (1,396) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 545 | ||||||||
Tax Rate | |||||||||
NOPAT | (1,388) | (1,941) | |||||||
Net income | (312) -75.80% | (1,288) -59.81% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,013 | 1,601 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 813 | ||||||||
Long-term debt | 60 | 41 | |||||||
Deferred revenue | 1,607 | ||||||||
Other long-term liabilities | 2,936 | 2,993 | |||||||
Net debt | 797 | (389) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (1,414) | (1,409) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 1,060 | 1,601 | |||||||
FCF | (2,099) | (1,753) | |||||||
| Balance | |||||||||
Cash | 76 | 430 | |||||||
Long term investments | |||||||||
Excess cash | 59 | 413 | |||||||
Stockholders' equity | (10,171) | (11,314) | |||||||
Invested Capital | 9,450 | 10,039 | |||||||
ROIC | |||||||||
ROCE | 192.36% | 109.49% | |||||||
| EV | |||||||||
Common stock shares outstanding | 59,242 | 37,768 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (1,386) | (1,395) | |||||||
EV/EBITDA | |||||||||
Interest | 149 | 7 | |||||||
Interest/NOPBT | |||||||||